Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
August 2018
-
Key ReleaseSOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutationSOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase…
-
Neuroscientists target Alzheimer’s “silent stage”
Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.
-
Key ReleaseNovartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance OfficerBasel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and…
-
Key ReleaseNovartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance OfficerBasel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D., den CEO von…
-
New drug manufacturing tools change pharma chemistry
The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.
-
Embracing big data to understand complex diseases
Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.
-
Discovery gives cystic fibrosis researchers new direction
Novartis-Harvard team identifies a new type of cell that is key to the disease.
July 2018
-
Meet Manuel Cobos, transplant surgeon and researcher
Follow Dr. Cobos as he works to provide a patient with a new liver and performs surgery using a tiny video camera.
-
Media ReleaseNovartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine preventionPatients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
-
Quest for a new measure of mental health
Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.
-
Media ReleaseSandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is…
-
Media ReleaseNovartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanomaPhase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with…
Pagination
- ‹ Previous page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- …
- 150
- › Next page